Sugi Predict

Sugi Predict / Compounds / SCHEMBL1595904

SCHEMBL1595904

SCHEMBL1595904

CCCCn1cc(NC(=O)Nc2ccc(Cl)cc2C)nc1C(=O)O

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.42
▸ SMN1; SMN2 Q16637 3/20 0.42
▸ RAB9A P51151 3/20 0.42
▸ NPC1 O15118 2/20 0.42
▸ SLC6A3 Q01959 1/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ ATM Q13315 1/20 0.40
▸ POLB P06746 2/20 0.40
▸ TP53 P04637 1/20 0.39
▸ IDH1 O75874 1/20 0.39
▸ GBA1 P04062 1/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ MAPK1 P28482 1/20 0.38
▸ LMNA P02545 1/20 0.38
▸ PKM P14618 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2569122 0.88 MAPT (0.40) MAPTSMN1; SMN2RAB9ANPC1SLC6A3
SCHEMBL27708352 0.87 MAPT (0.40) MAPTSMN1; SMN2RAB9ANPC1ATM
SCHEMBL2568640 0.86 MAPT (0.39) MAPTSMN1; SMN2RAB9ANPC1SLC6A3
SCHEMBL2572024 0.85 P2RX7 (0.48) MAPTSMN1; SMN2RAB9AKMT2APOLB
SCHEMBL13197811 0.85 EPHX2 (0.38) MAPTSMN1; SMN2RAB9ANPC1SLC6A3
SCHEMBL2565935 0.84 ALOX5 (0.41) MAPTSMN1; SMN2RAB9ANPC1ALDH1A1
SCHEMBL1594449 0.84 MEN1 (0.41) MAPTSMN1; SMN2RAB9ANPC1SLC6A3
SCHEMBL2570872 0.84 MAPK1 (0.39) MAPTSMN1; SMN2RAB9ANPC1SLC6A3
SCHEMBL2572465 0.84 MAPK1 (0.39) MAPTSMN1; SMN2RAB9ANPC1SLC6A3
SCHEMBL13197808 0.83 SLC6A3 (0.37) MAPTSMN1; SMN2RAB9ANPC1SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101128455-B Heterocyclylamide-substituted imidazoles AICURIS GMBH & CO KG 2013-01-16 — — CN disclosed
EP-1732901-B1 ANTIVIRAL 4-AMINOCARBONYLAMINO-SUBSTITUTED IMIDAZOLE COMPOUND AICURIS GMBH & CO KG (DE) 2011-11-02 — — EP disclosed
EP-1732901-B1 ANTIVIRAL 4-AMINOCARBONYLAMINO-SUBSTITUTED IMIDAZOLE COMPOUND AICURIS GMBH & CO KG (DE) 2011-11-02 — — EP disclosed
US-7919489-B2 e.g. 4-({[(4-Chloro-2-methylphenyl)amino]carbonyl}amino)-1-(cyclopropylmethyl)-1H-imidazole-2-carboxylic acid; antiviral agents, especially against cytomegaloviruses and other Herpes viridae; side effect reduction; antibiotic resistance AICURIS GMBH & CO. KG (DE) 2011-04-05 — — US disclosed
US-7919489-B2 e.g. 4-({[(4-Chloro-2-methylphenyl)amino]carbonyl}amino)-1-(cyclopropylmethyl)-1H-imidazole-2-carboxylic acid; antiviral agents, especially against cytomegaloviruses and other Herpes viridae; side effect reduction; antibiotic resistance AICURIS GMBH & CO. KG (DE) 2011-04-05 — — US disclosed
US-7919489-B2 e.g. 4-({[(4-Chloro-2-methylphenyl)amino]carbonyl}amino)-1-(cyclopropylmethyl)-1H-imidazole-2-carboxylic acid; antiviral agents, especially against cytomegaloviruses and other Herpes viridae; side effect reduction; antibiotic resistance AICURIS GMBH & CO. KG (DE) 2011-04-05 — — US disclosed
US-7767704-B2 Antiviral 4-aminocarbonylamino-substituted imidazole compounds AICURIS GMBH & CO. KG (DE) 2010-08-03 — — US disclosed
US-7767704-B2 Antiviral 4-aminocarbonylamino-substituted imidazole compounds AICURIS GMBH & CO. KG (DE) 2010-08-03 — — US disclosed
US-7767704-B2 Antiviral 4-aminocarbonylamino-substituted imidazole compounds AICURIS GMBH & CO. KG (DE) 2010-08-03 — — US disclosed
EP-1853582-B1 HETEROCYCLYLAMIDE-SUBSTITUTED IMIDAZOLES AICURIS GMBH & CO KG (DE) 2009-10-21 — — EP disclosed
US-20080176859-A1 HETEROCYCLYAMIDE-SUBSTITUTED IMIDAZOLES AICURIS GMBH & CO. KG (DE) 2008-07-24 — — US disclosed
US-20080176859-A1 HETEROCYCLYAMIDE-SUBSTITUTED IMIDAZOLES AICURIS GMBH & CO. KG (DE) 2008-07-24 — — US disclosed
US-20080176859-A1 HETEROCYCLYAMIDE-SUBSTITUTED IMIDAZOLES AICURIS GMBH & CO. KG (DE) 2008-07-24 — — US disclosed
US-20080004275-A1 Antiviral 4-Aminocarbonylamino-Substituted Imidazole Compounds BAYER HEALTHCARE AG (DE) 2008-01-03 — — US disclosed
US-20080004275-A1 Antiviral 4-Aminocarbonylamino-Substituted Imidazole Compounds BAYER HEALTHCARE AG (DE) 2008-01-03 — — US disclosed
US-20080004275-A1 Antiviral 4-Aminocarbonylamino-Substituted Imidazole Compounds BAYER HEALTHCARE AG (DE) 2008-01-03 — — US disclosed
EP-1732901-A1 ANTIVIRAL 4-AMINOCARBONYLAMINO-SUBSTITUTED IMIDAZOLE COMPOUND Bayer HealthCare AG (DE) 2006-12-20 — — EP disclosed
WO-2005092865-A1 ANTIVIRAL 4-AMINOCARBONYLAMINO-SUBSTITUTED IMIDAZOLE COMPOUND BAYER HEALTHCARE AG (DE) 2005-10-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176859-A1 HETEROCYCLYAMIDE-SUBSTITUTED IMIDAZOLES TPMT, TYMP, PAICS MAPT 2179/4885SMN1; SMN2 1972/4885RAB9A 1964/4885
US-20080004275-A1 Antiviral 4-Aminocarbonylamino-Substituted Imidazole Compounds IRF3, EIF2AK2, ZC3HAV1 MAPT 3312/4885SMN1; SMN2 2449/4885RAB9A 1907/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.